Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture-Reference-Cited by-同舟云学术

Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture

Published:1989-11 Issue:22 Volume:38 Page:4069-4074
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Schott Brigitte,Robert Jacques

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference27 articles.

1. Comparative mammalian metabolism of adriamycin and daunorubicin;Loveless;Cancer Res.,1978

2. Pharmacocinétique des nouvelles anthracyclines;Robert;Bull Cancer,1988

3. Pharmacokinetics of doxorubicin in sarcoma patients;Robert;Eur J Clin Pharmacol,1987

4. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients;Vrignaud;Eur J Cancer Clin Oncol,1985

5. Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites;Rahman;Semin Oncol,1984

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme;Pharmaceutical Research;2020-05

2. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters;Biochemical Pharmacology;2019-05

3. Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents;Investigational New Drugs;2017-03-10

4. Inhibition of human anthracycline reductases by emodin — A possible remedy for anthracycline resistance;Toxicology and Applied Pharmacology;2016-02

5. Epirubicin inhibits growth and alters the malignant phenotype of the U-87 glioma cell line;Molecular Medicine Reports;2015-08-12